Suppr超能文献

单核细胞增生李斯特菌与体外膜肺氧合支持下的新生儿严重呼吸衰竭。

Listeria monocytogenes and severe newborn respiratory failure supported with extracorporeal membrane oxygenation.

作者信息

Hirschl R B, Butler M, Coburn C E, Bartlett R H, Baumgart S

机构信息

Department of Surgery, Children's Hospital of Philadelphia, Pa.

出版信息

Arch Pediatr Adolesc Med. 1994 May;148(5):513-7. doi: 10.1001/archpedi.1994.02170050071013.

Abstract

OBJECTIVE

To determine the efficacy of extracorporeal membrane oxygenation (ECMO) in newborn infants with early-onset Listeria monocytogenes infection, necrotizing pneumonia, and severe respiratory failure.

DESIGN

Patient series.

SETTING

ECMO referral centers.

PARTICIPANTS

The Extracorporeal Life Support Organization Registry database of patients supported with ECMO between 1975 and 1991.

INTERVENTION

ECMO.

MEASUREMENTS AND RESULTS

Nine neonates were identified who were supported with ECMO for severe respiratory failure associated with L monocytogenes infection. Microbiologic studies demonstrated L monocytogenes organisms in the blood of all infants, and pneumonia was diagnosed by roentgenogram and/or isolation of L monocytogenes organisms in tracheobronchial secretions. All infants experienced progressive respiratory deterioration by age 36 hours and were placed on venoarterial bypass by 96 hours, having met institution-based criteria predictive of 80% to 90% mortality. The duration of ECMO for patients with Listeria infection (median, 210 hours; range, 137 to 454 hours) was prolonged compared with the duration of ECMO for neonates in all other registry diagnostic categories (median, 114 hours; range, 1 to 744 hours; N = 5146, P = .035). Six of the nine infants recovered completely.

CONCLUSIONS

These data suggest that ECMO is efficacious in patients with severe respiratory failure secondary to Listeria sepsis. Prolonged time on bypass should be expected when Listeria sepsis is associated with severe necrotizing pneumonia.

摘要

目的

确定体外膜肺氧合(ECMO)对早发型单核细胞增生李斯特菌感染、坏死性肺炎及严重呼吸衰竭的新生儿的疗效。

设计

病例系列研究。

地点

ECMO转诊中心。

参与者

1975年至1991年间接受ECMO支持的患者的体外生命支持组织注册数据库。

干预措施

ECMO。

测量指标及结果

确定了9例因单核细胞增生李斯特菌感染导致严重呼吸衰竭而接受ECMO支持的新生儿。微生物学研究显示所有婴儿血液中均有单核细胞增生李斯特菌,通过X线胸片和/或气管支气管分泌物中单核细胞增生李斯特菌的分离确诊为肺炎。所有婴儿在36小时龄时均出现进行性呼吸恶化,96小时时均符合基于机构标准的预测死亡率为80%至90%的情况,遂进行静脉-动脉体外循环。与所有其他注册诊断类别的新生儿相比,李斯特菌感染患者的ECMO持续时间(中位数为210小时;范围为137至454小时)延长(中位数为114小时;范围为1至744小时;N = 5146,P = 0.035)。9例婴儿中有6例完全康复。

结论

这些数据表明,ECMO对李斯特菌败血症继发的严重呼吸衰竭患者有效。当李斯特菌败血症与严重坏死性肺炎相关时,预计体外循环时间会延长。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验